Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Apr 28;2(5):484–495. doi: 10.1158/1940-6207.CAPR-08-0173

Fig. 4.

Fig. 4

Effect of daily orally-administered MSeA and MSeC starting from 8 weeks of age on serum IGF-1 levels at (A) 18 weeks and (B) 26 weeks of age and on (C) the IGF-1R phosphorylation status of the dorsolateral prostate of TRAMP mice at 18 weeks of age detected by immunobloting. IGF-1 was detected by ELISA, n=10 mice per group. *Indicate different from respective water-group at P<0.05.

HHS Vulnerability Disclosure